MLYS
When insiders reach for the exit
Mineralys Therapeutics got a fresh dose of the classic Wall Street question: why are they selling? According to the filing, 30,000 shares were sold indirectly through trust entities on April 10 for about $1.64 million, and another 57,180 shares were sold in a separate stretch ending April 16 for roughly $826,000.
The not-so-subtle signal
That second sale chopped direct holdings down to 408,160 shares, while the trust-entity sale reduced indirect ownership from 113,814 shares to 83,814. In plain English: the insiders are still plenty invested, but they’ve clearly been taking some chips off the table.
Why you should care
Insider selling is not a flashing red siren on its own — people sell for taxes, diversification, or a dozen boring reasons. But when a company is in the spotlight, multiple sales can make investors wonder whether the easy money has already been made.
Big picture
For MLYS holders, this is less about panic and more about pattern-spotting. One sale? Meh. Several sales close together? Now you’re at least leaning in and checking whether the company’s next catalyst can overpower the insider cash-out vibe.